{"title":"Is it necessary to increase the dose of levothyroxine in patients with hypothyroidism who use omeprazole?","authors":"Raquel de Carvalho Abi-Abib, Mário Vaisman","doi":"10.1590/0004-2730000002997","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>It is believed that gastric pH interferes in levothyroxine absorption. Omeprazole, which acts by blocking the secretion of gastric acid, might interfere in hypothyroidism control in patients using levothyroxine and this effect could be dose dependent. The present study aimed to investigate this possibility.</p><p><strong>Subjects and methods: </strong>Twenty-one patients with primary hypothyroidism who had been using a stabilized levothyroxine dosage for at least one year were selected and randomly assigned to take omeprazole at the dosage of 40 mg or 20 mg per day. The mean levels of thyroid-stimulating hormone (TSH) before and 3 months after omeprazole usage were compared in the entire sample and in each group.</p><p><strong>Results: </strong>Ten patients concluded the entire treatment protocol in the 20 mg group and nine patients in the 40 mg group. There was no significant difference in TSH levels before and 3 months after omeprazole treatment in the entire patient sample (median levels: 2.28 vs. 2.30 mU/L, respectively: p = 0.56). Analysis of each subgroup (20 and 40 mg) showed no significant variation in TSH levels before and 3 months after omeprazole treatment (median levels: 2.24 vs. 2.42 mU/L, p = 0.62, and 2.28 vs. 2.30 mU/L, p = 0.82, respectively). No significant difference in the absolute (p = 0.93) or relative (p = 0.87) delta were observed between the two subgroups.</p><p><strong>Conclusion: </strong>Omeprazole in the dosage of 20 or 40 mg/day does not interfere in a clinically relevant manner in the treatment of patients with hypothyroidism that was previously under control.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000002997","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de endocrinologia e metabologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/0004-2730000002997","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11
Abstract
Objective: It is believed that gastric pH interferes in levothyroxine absorption. Omeprazole, which acts by blocking the secretion of gastric acid, might interfere in hypothyroidism control in patients using levothyroxine and this effect could be dose dependent. The present study aimed to investigate this possibility.
Subjects and methods: Twenty-one patients with primary hypothyroidism who had been using a stabilized levothyroxine dosage for at least one year were selected and randomly assigned to take omeprazole at the dosage of 40 mg or 20 mg per day. The mean levels of thyroid-stimulating hormone (TSH) before and 3 months after omeprazole usage were compared in the entire sample and in each group.
Results: Ten patients concluded the entire treatment protocol in the 20 mg group and nine patients in the 40 mg group. There was no significant difference in TSH levels before and 3 months after omeprazole treatment in the entire patient sample (median levels: 2.28 vs. 2.30 mU/L, respectively: p = 0.56). Analysis of each subgroup (20 and 40 mg) showed no significant variation in TSH levels before and 3 months after omeprazole treatment (median levels: 2.24 vs. 2.42 mU/L, p = 0.62, and 2.28 vs. 2.30 mU/L, p = 0.82, respectively). No significant difference in the absolute (p = 0.93) or relative (p = 0.87) delta were observed between the two subgroups.
Conclusion: Omeprazole in the dosage of 20 or 40 mg/day does not interfere in a clinically relevant manner in the treatment of patients with hypothyroidism that was previously under control.
目的:认为胃pH干扰左甲状腺素的吸收。奥美拉唑通过阻断胃酸分泌起作用,可能干扰左甲状腺素患者甲状腺功能减退的控制,且这种影响可能是剂量依赖性的。本研究旨在探讨这种可能性。研究对象和方法:选择21例使用稳定左甲状腺素剂量至少1年的原发性甲状腺功能减退患者,随机分配服用奥美拉唑,剂量为40mg / d或20mg / d。比较奥美拉唑用药前和用药后3个月全组和各组的平均促甲状腺激素(TSH)水平。结果:20mg组10例患者完成整个治疗方案,40mg组9例患者完成整个治疗方案。在整个患者样本中,奥美拉唑治疗前和治疗后3个月的TSH水平无显著差异(中位水平分别为2.28 vs 2.30 mU/L: p = 0.56)。各亚组(20和40 mg)分析显示,奥美拉唑治疗前和治疗后3个月TSH水平无显著变化(中位水平分别为2.24 vs 2.42 mU/L, p = 0.62, 2.28 vs 2.30 mU/L, p = 0.82)。两亚组间δ绝对值(p = 0.93)和δ相对值(p = 0.87)均无显著差异。结论:奥美拉唑在20或40 mg/天的剂量下对先前控制的甲状腺功能减退患者的治疗没有临床相关的影响。